METHODS FOR USING CD137 LIGAND AS A BIOMARKER FOR TREATMENT WITH ANTI-CD137 ANTIBODY

摘要

Provided herein are methods relating to the use of CD137 Ligand (CD137L) expression; methods relating to the use of CD137L expression as a biomarker; and methods for predicting, assessing, and/or aiding in assessment of responsiveness of a subject in need thereof to treatment with particular anti-cancer therapies (e.g., an anti-CD137 antibody, a checkpoint blockade immunotherapy).